Oncolytic Herpes Simplex Virus Prevents Premalignant Lesions from Progressing to Cancer

Area of Science:

• Oncology
• Virology
• Cancer Prevention

Background:

• Early detection and treatment of precancerous lesions are crucial for cancer prevention.
• Oncolytic viruses show promise in treating solid tumors, with NV1066 demonstrating selective cancer cell killing.
• The potential of oncolytic viruses to treat premalignant lesions remains an area of active investigation.

Purpose of the Study:

• To evaluate the efficacy of NV1066, an oncolytic herpes simplex-1 virus, in treating precancerous oral lesions.
• To determine if NV1066 can prevent cancer formation by targeting dysplastic and cancerous cells.
• To assess the infectivity of NV1066 in various stages of oral carcinogenesis.

Main Methods:

• An oral chemical carcinogenesis model was established in hamsters.
• NV1066 was administered via intramucosal injection to assess its infectivity and therapeutic effects.
• Lesion development was monitored over a 7-week treatment period.

Main Results:

• NV1066 consistently infected dysplastic cells, carcinoma in situ, and squamous cell carcinoma.
• Animals treated with NV1066 exhibited a 3-fold reduction in lesion number and a 4-fold reduction in lesion size compared to controls.
• Infectivity of NV1066 was observed to be potentially dependent on the nectin-1 receptor.

Conclusions:

• NV1066 demonstrates the ability to infect and treat both oral squamous cell carcinoma and premalignant lesions.
• Treatment with NV1066 significantly delays cancer progression by targeting precancerous lesions.
• The oncolytic virus NV1066 holds potential as a novel cancer prevention agent.